60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Short Interest Update

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 130,700 shares, a growth of 95.1% from the March 31st total of 67,000 shares. Based on an average daily volume of 335,700 shares, the short-interest ratio is currently 0.4 days. Currently, 1.5% of the shares of the company are short sold.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research note on Wednesday, April 3rd.

60 Degrees Pharmaceuticals Stock Performance

Shares of 60 Degrees Pharmaceuticals stock remained flat at $0.24 during trading on Friday. The stock had a trading volume of 94,376 shares, compared to its average volume of 94,055. The stock has a 50 day moving average price of $0.27 and a two-hundred day moving average price of $0.55. 60 Degrees Pharmaceuticals has a twelve month low of $0.22 and a twelve month high of $8.65.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last posted its quarterly earnings data on Monday, April 1st. The company reported ($0.44) EPS for the quarter. The firm had revenue of ($0.10) million during the quarter, compared to analyst estimates of $0.06 million. Research analysts forecast that 60 Degrees Pharmaceuticals will post -0.29 earnings per share for the current year.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.